Clinical Trials Browser

Phase 2 × tocotrienol, delta × 1 year × Clear all

NCT06519097 2025-11-13

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms